BioNTech's (BNTX) "Buy" Rating Reiterated at Canaccord Genuity Group

Key Points

• Canaccord Genuity reiterated a Buy rating on BioNTech with a $171 price target, implying roughly an 88% upside from the current share price.
• The sell‑side consensus is a Moderate Buy—12 analysts rate Buy, four Hold and one Sell—with an average price target of $134.33.
• Operationally BioNTech reported Q4 beats and a strong balance sheet, but management's weak FY‑2026 revenue guidance (~€2.0–2.3bn), the co‑founders' planned departure and attendant litigation/governance headlines have sparked volatility and selling pressure.

BioNTech (NASDAQ:BNTX - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Canaccord Genuity Group in a report released on Wednesday,Benzinga reports. They presently have a $171.00 target price on the stock. Canaccord Genuity Group's target price would indicate a potential upside of 88.31% from the stock's current price.

A number of other equities research analysts also recently issued reports on the company. The Goldman Sachs Group reaffirmed a "buy" rating on shares of BioNTech in a research note on Wednesday. Raymond James Financial reiterated an "outperform" rating on shares of BioNTech in a report on Tuesday. Jefferies Financial Group dropped their price objective on shares of BioNTech from $151.00 to $138.00 and set a "buy" rating for the company in a report on Tuesday. HC Wainwright reaffirmed a "buy" rating and set a $140.00 target price on shares of BioNTech in a report on Thursday, December 11th. Finally, Truist Financial set a $155.00 price target on shares of BioNTech in a research report on Tuesday. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $134.33.

BioNTech Price Performance

NASDAQ:BNTX traded up $6.92 on Wednesday, reaching $90.81. The stock had a trading volume of 3,257,613 shares, compared to its average volume of 1,144,150. The stock has a fifty day moving average price of $106.73 and a 200-day moving average price of $102.83. BioNTech has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a market capitalization of $20.45 billion, a P/E ratio of -34.65 and a beta of 1.51. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01.

Institutional Trading of BioNTech

Several large investors have recently added to or reduced their stakes in BNTX. Dodge & Cox boosted its position in shares of BioNTech by 315.7% during the third quarter. Dodge & Cox now owns 3,647,091 shares of the company's stock worth $359,676,000 after acquiring an additional 2,769,654 shares during the last quarter. BNP Paribas Financial Markets boosted its position in BioNTech by 43.0% in the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock valued at $150,235,000 after buying an additional 474,796 shares during the period. GSK plc bought a new position in shares of BioNTech during the 4th quarter worth $84,711,000. Franklin Resources Inc. raised its stake in BioNTech by 76.8% in the second quarter. Franklin Resources Inc. now owns 751,998 shares of the company's stock worth $80,065,000 after buying an additional 326,556 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of BioNTech by 5.6% in the 2nd quarter. Invesco Ltd. now owns 681,100 shares of the company's stock valued at $72,517,000 after buying an additional 35,958 shares in the last quarter. Institutional investors own 15.52% of the company's stock.

Trending Headlines about BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Analyst support remains intact: Goldman Sachs reaffirmed a "buy" rating, and Jefferies and BMO both cut price targets but kept buy/outperform stances — signals that many sell‑side investors still see substantial upside. MarketScreener StreetInsider (Jefferies) Benzinga (BMO)
• Positive Sentiment: Q4 results beat headline EPS and revenue estimates and the company reports a very strong balance sheet (~€17.2bn) plus a deep late‑stage oncology/mRNA pipeline — fundamentals that make a "buy the dip" thesis plausible for some investors. GlobeNewswire
• Neutral Sentiment: Co‑founders Sahin and Türeci plan to form a new mRNA company; BioNTech will transfer certain rights/tech and take a minority stake with potential milestones/royalties — this can be read as both a loss of founders and a structured value‑capture arrangement. GlobeNewswire (co-founders)
• Negative Sentiment: Management issued weaker FY‑2026 revenue guidance (roughly €2.0–2.3bn) well below street expectations, which prompted investor concerns about near‑term growth and drove recent selling pressure. GlobeNewswire (guidance)
• Negative Sentiment: Founder departures and the disappointing outlook triggered sharp headlines and heavy selling — several outlets reported a double‑digit intraday plunge after the news, increasing volatility and fear among short‑term holders. Reuters (departure) Blockonomi (plunge)
• Negative Sentiment: Shareholder litigation interest (Johnson Fistel) and headlines about governance/executive changes add legal/PR risk that can pressure the stock while uncertainties persist. GlobeNewswire (litigation)

BioNTech Company Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.